Brain Health 360°: Preventing, Diagnosing, and Slowing Dementia
Executive Summary
Faced with the great challenge of cognitive decline, modern medicine is moving from a passive approach to proactive and optimistic intervention. The accumulated knowledge demonstrates that it is possible to significantly influence the risk of dementia and the course of the disease. This executive summary distills the full review into a practical guide, and presents the main recommendations, ranked by their level of research certainty, in order to help prioritize clinical actions. Key levels of certainty: (High certainty | Moderate certainty | Low certainty/promising)
1. Early diagnosis: the key to effective intervention
Proactive review
A brief annual cognitive assessment should be considered for every patient over the age of 65, and proactively ask about memory. It can be performed at earlier ages for people at high risk.
Choosing the right tool
The MoCA test should be preferred over the MMSE for detecting mild cognitive impairment (MCI).
Informed use of biomarkers
Innovative blood tests (such as p-tau) should be used as an initial screening tool, but a positive result should be confirmed with a “gold standard” test (lumbar puncture or PET) before initiating specific treatment.
2. Lifestyle: The base of the prevention pyramid
Aggressive management of vascular risk factors
Aim for target values of blood pressure < 120/80 and LDL level < 70 mg/dL, along with strict control of blood sugar levels.
Exercise prescription
Incorporate interval training (HIIT) and strength training, 3-4 times a week, in order to increase BDNF levels (“brain fertilizer”).
Quality sleep
Aim for 7.5 to 8 hours of sleep per night and treat sleep disorders (such as sleep apnea).
MIND diet
Adopt a Mediterranean-style diet, with an emphasis on leafy greens, berries, nuts, and fish.
Additional interventions
Actively treat hearing loss, encourage social engagement, manage stress, and maintain oral hygiene (visit a hygienist).
3. Nutritional supplements: an informed and goal-based approach (complementing deficiencies)
B vitamins
For patients with MCI and homocysteine levels > 9, consider supplementation according to the VITACOG formula (folic acid 0.8 mg, B12 0.5 mg, B6 20 mg).
Omega-3 and vitamin D
Aim for optimal levels measured in blood tests (omega-3 index > 8%; vitamin D in the high range of the norm), and adjust supplementation as needed.
Creatine
A supplement of 5 grams per day can be considered to support the muscle mass essential for physical activity, with the potential for secondary cognitive benefit.
4. Drug therapy: the new frontier of treatment
Amyloid-removing antibodies (Lecanemab, Donanemab)
These treatments should be considered for patients with MCI or mild Alzheimer’s, and with evidence of brain amyloid pathology. Treatment requires expert management and monitoring.
Other promising drugs
GLP-1 agonists should be considered for high-risk patients with diabetes or obesity. Hormone replacement therapy (HRT) should be discussed with postmenopausal women.
Introduction: A silent epidemic with enormous costs
One of the central tensions in modern medicine lies between the human desire to live as long as possible and the equally intense desire to maintain mental clarity and high cognitive function. For many, quality of life, and in particular mental acuity, is increasingly important than longevity alone.
Dementia (Hebrew: שִׁתָּטּיוֹן) is the most extreme manifestation of cognitive decline. Alzheimer’s disease, the most common cause of dementia, is seen by many as the most feared disease, more so than heart disease and cancer.
In contrast to these diseases, Alzheimer’s disease does not “kill” directly. Death is often the result of complications resulting from severe functional decline: inability to care for basic needs leads to pneumonia due to aspiration of food or secretions, difficulty eating, or severe infections caused by pressure sores due to immobility.
Thus, brain degeneration eventually becomes one of the leading causes of death in the Western world.
The numbers behind this silent epidemic are alarming. The incidence of Alzheimer’s disease is increasing faster than cancer and heart disease. This can be attributed in part to improved diagnostic capabilities and increased life expectancy, but these figures do not explain the whole picture.
The extent of the disease: As of 2024, an estimated 7 million Americans are living with Alzheimer’s. The number is projected to jump to 12.7 million by 2050 (1).
The economic cost: The direct cost of treating the disease is estimated to be At about $360 billion per year, plus $346 billion in “indirect costs,” mostly due to lost work hours for family caregivers.
Mortality rates: Since 2000, while mortality from heart disease has fallen by 7%, mortality from Alzheimer’s has risen by 141%.
The most important point for us is that the pathological processes in the brain, that is, the physical damage that causes the disease, begin to occur 15-20 years before the first symptoms appear. This long period of time creates a “golden window of opportunity” in which it is possible to act, prevent, or at least significantly delay the onset of the disease (2).
2. Understanding Dementia and Alzheimer’s Disease
What is Dementia and Alzheimer’s?
Alzheimer’s is a degenerative disease of the brain that affects cognitive abilities. “Cognition” is an umbrella term for a variety of higher mental functions, such as short- and long-term memory, problem-solving ability, orientation and executive functions (e.g., planning and decision-making). It is important to emphasize that, like cancer, Alzheimer’s is not a uniform disease. There are different subtypes: in some cases, the main damage will be to short-term memory, and in other cases, executive functions or the ability to navigate will be more significantly affected (3).
Disproportionately affected in women
One of the most worrying statistics about Alzheimer’s is the gender gap: the disease affects women at twice the rate as men. The immediate explanation, that women live longer on average, is not enough to explain such a large gap.
A central hypothesis links this to menopause. The sharp decline in the hormone estrogen, which provides the brain with neuroprotection, exposes the female brain to greater vulnerability. The numbers clearly show this: a man’s risk of developing dementia during his lifetime is about 11